Prognostic and clinicopathological significance of SR-B1 in solid tumors: A meta-analysis

• Published in: Pathology, research and practice research and practice, 2020-04, Vol.216 (4), p.152849-152849, Article 152849
• Main Authors: Wang, Min, Chao, Ce, Luo, Guanghua, Wang, Bin, Zhan, Xianghong, Di, Dongmei, Qian, Yongxiang, Zhang, Xiaoying
• Format: Article
• Language: English
• Subjects: Biomarkers, Tumor - metabolism; CD36 Antigens - metabolism; Clinicopathological features; Humans; Meta-analysis; Neoplasms - pathology; Prognosis; Solid tumor; SR-B1
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2020.152849

The expression of cell surface receptors is abnormal in malignant tumors. The scavenger receptor class B type I (SR-B1) is an integral membrane glycoprotein receptor that facilitates the selective uptake of cholesterol by malignant cells. Accumulated studies investigated the prognostic role of SR-B1 in many solid tumors, such as breast cancer, lung cancer and so on. However, the conclusions remain undefined. Therefore, we conducted this meta-analysis to obtain more accurate evaluation of prognostic significance of SR-B1 in solid tumors. We searched PubMed, Embase, Web of science and Cochrane library for eligible studies published before November 2018. The included studies investigated the association between the SR-B1 level and clinicopathological features including survival outcomes in solid tumors. Hazard ratios (HRs) with 95% confidence intervals (CIs) were adopted to assess the survival outcomes and odds ratio (ORs) with 95% confidence intervals (CIs) were pooled to evaluated the clinicopathological features. A total of 10 studies involving 2585 patients were included in this meta-analysis. The results showed that low SR-B1 level was significantly correlated with earlier tumor grade (pooled OR = 2.09, 95%CI = 1.28–3.43, P = 0.001), less nodal involvement (pooled OR = 2.07, 95%CI = 1.43–3.0, P < 0.001), less distant metastasis (OR = 19.8, 95%CI = 2.58–151.65, P = 0.004), smaller tumor size (OR = 2.34, 95%CI = 1.53–3.57, P < 0.001), earlier TNM stage (OR = 3.77, 95%CI = 1.67–8.48, P = 0.001), lower recurrence (HR = 1.98, 95%CI = 1.57–2.49, P = 0.000), and better OS (HR = 1.99, 95%CI = 1.70–2.31, P = 0.000). The low expression of SR-B1 was significantly associated with better clinicopathological status and longer survival in patients with solid tumors. SR-B1 might act as a promising prognostic biomarker for solid tumors.